Genomics, In-Vitro and Sales - Clinical Research Informer

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test

The Pharma Data

AUGUST 27, 2020

FoundationOne Liquid CDx analyses more than 300 cancer-related genes and multiple genomic signatures to help inform treatment decisions for all solid tumour cancers. FoundationOne Liquid CDx adds to Foundation Medicine’s genomic testing portfolio supporting Roche’s mission to deliver truly personalised healthcare.

FDA Approval

FDA Approval Genome Genomics Gene

Roche announces the repurchase of the equity stake held by Novartis in Roche

The Pharma Data

NOVEMBER 5, 2021

Roche confirms the outlook for the full year and expects a mid-single-digit sales growth at constant exchange rates. Core EPS growth at constant exchange rates is targeted to be broadly in line with sales growth. Roche intends to cancel the shares repurchased from Novartis after completion of the repurchase.

In-Vitro

In-Vitro Sales Genome Genomics

Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers

The Pharma Data

DECEMBER 14, 2020

engine along with algorithms tuned to predict BBB permeability played an important role in helping determine which CNS cancers and which genomically-defined subtypes of CNS cancer should be prioritized for development. . We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I.

Drugs

Drugs Genome Genomics DNA

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Roche ranked as one of the top three most sustainable healthcare companies in the Dow Jones Sustainability Indices for the thirteenth year running

The Pharma Data

NOVEMBER 14, 2021

The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategy Roche performed particularly well in Operational Eco-Efficiency, Environmental and Social Reporting. This is based on an in-depth analysis of economic, social and environmental performance.

In-Vitro

In-Vitro Medicine Genome Genomics

Progenity, Inc. Prices $75.0 Million Convertible Senior Notes Offering – Dec 03, 2020

The Pharma Data

DECEMBER 2, 2020

The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million principal amount of notes. The notes will mature on December 1, 2025, unless earlier repurchased, redeemed or converted.

Sales

Sales In-Vitro Containment Development

Progenity Announces Pricing of Public Offering of Common Stock – Dec 03, 2020

The Pharma Data

DECEMBER 2, 2020

The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. SAN DIEGO, Dec.

In-Vitro

In-Vitro Sales Containment Development

Top 10 Fastest Growing Medical Device Companies in 2023

XTalks

DECEMBER 11, 2023

Medical device companies continue to maintain a crucial role in enhancing patient care and diagnostic precision in 2023. Let’s examine the list of the top ten fastest growing medical device companies in 2023, ranked by their compound annual growth rate (CAGR). In 2021, Axonics achieved an impressive revenue of $180.3

Production

Production Sales In-Vitro Development

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020

The Pharma Data

SEPTEMBER 16, 2020

New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers. New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Join this event on Roche’s LinkedIn page here. Roche highlights featured at ESMO Virtual Congress 2020.

HR

HR Medicine Hormones Trials

Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer

The Pharma Data

SEPTEMBER 6, 2020

We remain committed to finding personalised treatment options for people with cancer based on specific genomic or molecular alterations, and we look forward to partnering with Blueprint Medicines to further explore the potential of Gavreto across multiple RET-altered tumour types.”. months, not reached). 2 The most common adverse reactions (?

FDA Approval

FDA Approval Medicine In-Vitro Genetics

Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer

The Pharma Data

MAY 4, 2021

Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study. Tecentriq approval offers an alternative to chemotherapy for all eligible patients. We are delighted to bring Tecentriq to people in the EU with this specific type of lung cancer,” said Levi Garraway, M.D.,

Protein

Protein HR In-Vitro Medicine

Roche reports good half-year results

The Pharma Data

JULY 21, 2021

Group sales up 8% 1 at constant exchange rates (CER); 5% in Swiss francs. Pharmaceuticals Division sales decline 3%; sales grow 4% in the second quarter, following a first-quarter decrease of 9%; newly launched medicines (+30%) compensate for the continued impact from biosimilars. [Ad hoc announcement pursuant to Art.

Sales

Sales Medicine Antibody In-Vitro

Anbio Biotechnology IPO Fuels In Vitro Diagnostics Innovation

XTalks

FEBRUARY 28, 2025

The capital raised will boost the companys expansion of its sales and distribution network, support R&D and enhance overall working capital. Anbio offers an extensive portfolio of in vitro diagnostics (IVD) products tests performed outside the human body to address diverse diagnostic needs. billion by 2031.

In-Vitro

In-Vitro Sales Production Genome

Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19

The Pharma Data

JULY 23, 2021

The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act. “Ronapreve has been shown to improve survival in high-risk, non-hospitalised COVID-19 patients by reducing the risk of hospitalisation and death.

Antibody

Antibody Medicine Production In-Vitro

Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children

The Pharma Data

JUNE 26, 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. The EUA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalised patients. Roche’s Chief Medical Officer and Head of Global Product Development. FDA in this setting, but the U.S.

Clinical Trials

Clinical Trials Clinical Trials In-Vitro Antibody

Clinical Research Informer

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test

Roche announces the repurchase of the equity stake held by Novartis in Roche

Webinars

Trending Sources

Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers

Webinars

Roche ranked as one of the top three most sustainable healthcare companies in the Dow Jones Sustainability Indices for the thirteenth year running

Progenity, Inc. Prices $75.0 Million Convertible Senior Notes Offering – Dec 03, 2020

Progenity Announces Pricing of Public Offering of Common Stock – Dec 03, 2020

Top 10 Fastest Growing Medical Device Companies in 2023

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020

Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer

Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer

Roche reports good half-year results

Anbio Biotechnology IPO Fuels In Vitro Diagnostics Innovation

Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19

Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children

Stay Connected